Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study

Oncel I., SANCAR M., KONUŞKAN B. , Arioz F., TEZCAN S., ARMAN KANDIRMAZ E., ...Daha Fazla

PEDIATRIC NEUROLOGY, cilt.110, ss.59-63, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier


Background: Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis.